JETA Molecular is a molecular diagnostics company focused on commercialization of advanced technologies that will change the way transplantation medicine is practiced today. Early detection of transplant rejection or disease relapse is critical for the adjustment of a transplant recipient’s treatment regime, graft survival and higher quality of life for patients. JETA’s tests will provide best in class solutions for post-transplant monitoring of transplant rejection and disease relapse. JETA’s solutions will enable new applications and will translate into better patient care and survival rates.